No connection

Search Results

AMPH

BEARISH
$18.18 Live
Amphastar Pharmaceuticals, Inc. · NASDAQ
Target $29.0 (+59.5%)
$17.03 52W Range $31.26

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Mar 14, 2026
Market cap
$835.41M
P/E
8.96
ROE
12.9%
Profit margin
13.6%
Debt/Equity
0.83
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
AMPH exhibits strong deterministic health with a Piotroski F-Score of 7/9, indicating solid operational efficiency and financial stability, though the absence of an Altman Z-Score raises concern about default risk. The stock trades at a discount to its Graham Number ($28.09) and intrinsic value ($14.21), suggesting undervaluation on a defensive basis. However, this is overshadowed by deteriorating fundamentals: negative revenue and earnings growth (YoY -1.8% and -31.0%), declining quarterly earnings, and a significant 36.4% drop in price over the past month. Insider selling activity further undermines confidence, with $0.95M in sales over six months despite no buy activity.

Key Strengths

Piotroski F-Score of 7/9 indicates strong financial health and operational efficiency
Graham Number of $28.09 suggests defensive undervaluation relative to intrinsic safety margin
High gross margin (49.46%) and operating margin (19.45%) reflect strong pricing power and cost control
Low debt-to-equity ratio (0.83) and high current ratio (4.02) signal strong liquidity and low leverage risk
Analyst consensus is 'buy' with a target price of $29.00, implying upside potential

Key Risks

Negative year-over-year earnings growth (-31.0%) and revenue decline (-1.8%) indicate deteriorating business momentum
Recent insider selling of $0.95M over six months signals potential lack of confidence from management
Stock has declined 36.4% in one month and 51.1% over three years, reflecting prolonged underperformance
No dividend and zero payout ratio eliminate income appeal and signal reinvestment focus without clear growth
Technical trend is bearish (0/100), confirming negative momentum and weak price action
AI Fair Value Estimate
Based on comprehensive analysis
$14.21
-21.8% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
50
Moderate
Value
72
Future
35
Past
68
Health
75
Dividend
0
AI Verdict
neutral-to-bearish
Key drivers: Strong Piotroski F-Score and liquidity metrics, Significant earnings and revenue decline, Negative technical momentum and insider selling, Undervaluation on Graham basis but not supported by growth, Lack of Altman Z-Score introduces uncertainty
Confidence
85%
Value
72/100

Ref P/E, PEG, Graham Number

Positives
  • Current price ($18.18) is below Graham Number ($28.09)
  • Price/Book (1.05) and P/E (8.96) are low relative to sector
  • Intrinsic value estimate ($14.21) suggests downside protection
Watchpoints
  • P/E of 8.96 is misleading due to negative earnings growth
  • No PEG ratio available, limiting growth-adjusted valuation
  • Stock has underperformed for years despite low valuation
Future
35/100

Ref Growth rates

Positives
  • Analyst target price of $29.00 implies 60% upside
  • Some recent quarters beat estimates (e.g., +32.2% surprise in 2024 Q1)
Watchpoints
  • Negative YoY earnings growth (-31.0%) and Q/Q decline (-35.7%)
  • Revenue growth is negative (-1.8%)
  • Most recent EPS growth is -21.5% Q/Q
  • No visible recovery in forward guidance
Past
68/100

Ref Historical trends

Positives
  • Historical earnings surprises have been positive in many quarters (e.g., +82.5% in 2023 Q1)
  • Consistent profitability with stable margins over time
  • Piotroski F-Score of 7/9 reflects strong historical performance
Watchpoints
  • Recent earnings trajectory shows clear deterioration
  • Five of last six quarters show declining EPS
  • 2026 Q1 missed estimates by 20.5%
Health
75/100

Ref Altman Z-Score, Piotroski F-Score

Positives
  • Piotroski F-Score of 7/9 indicates strong financial health
  • Low debt-to-equity (0.83) and high current ratio (4.02) suggest resilience
  • Positive operating and gross margins
Watchpoints
  • No Altman Z-Score available, which is a critical gap for distress risk assessment
  • High cash levels not quantified, limiting full health evaluation
Dividend
0/100

Ref Yield, Payout

Positives
No standout positives identified.
Watchpoints
  • No dividend yield or payout ratio
  • Dividend strength is 0/100
  • No income stream for investors

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$18.18
Analyst Target
$29.0
Upside/Downside
+59.5%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for AMPH and closest competitors.

Updated 2026-03-13
AMP
Amphastar Pharmaceuticals, Inc.
Primary
5Y
-5.1%
3Y
-51.1%
1Y
-30.7%
6M
-35.2%
1M
-36.4%
1W
-6.0%
TLR
Tilray Brands, Inc.
Peer
5Y
-95.8%
3Y
-68.9%
1Y
+58.9%
6M
-54.5%
1M
+15.1%
1W
+6.4%
MNK
MannKind Corporation
Peer
5Y
-36.3%
3Y
-32.0%
1Y
-40.8%
6M
-46.3%
1M
-1.1%
1W
+6.6%
SPR
ARS Pharmaceuticals, Inc.
Peer
5Y
-78.3%
3Y
+19.2%
1Y
-45.0%
6M
-18.6%
1M
-1.4%
1W
+1.6%
TBP
Theravance Biopharma, Inc.
Peer
5Y
-25.6%
3Y
+44.6%
1Y
+83.1%
6M
+16.8%
1M
+16.7%
1W
+1.3%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
8.96
Forward P/E
5.21
PEG Ratio
N/A
P/B Ratio
1.05
P/S Ratio
1.16
EV/Revenue
1.66
EV/EBITDA
5.44
Market Cap
$835.41M

Profitability

Profit margins and return metrics

Profit Margin 13.63%
Operating Margin 19.45%
Gross Margin 49.46%
ROE 12.9%
ROA 6.37%

Growth

Revenue and earnings growth rates

Revenue Growth -1.8%
Earnings Growth -31.0%
Q/Q Revenue Growth N/A
Q/Q Earnings Growth -35.7%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.83
Moderate
Current Ratio
4.02
Strong
Quick Ratio
2.8
Excellent
Cash/Share
$6.23

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-06
$N/A
2026-02-26
$0.73
-20.5% surprise
2025-11-06
$0.93
+12.7% surprise
2025-08-07
$0.85
+14.6% surprise

Healthcare Sector Comparison

Comparing AMPH against 560 companies in the Healthcare sector (34 bullish, 167 neutral, 359 bearish)
P/E Ratio
8.96
This Stock
vs
75.44
Sector Avg
-88.1% (Discount)
Return on Equity (ROE)
12.9%
This Stock
vs
-88.14%
Sector Avg
-114.6% (Below Avg)
Profit Margin
13.63%
This Stock
vs
-16.28%
Sector Avg
-183.7% (Weaker)
Debt to Equity
0.83
This Stock
vs
2.66
Sector Avg
-68.8% (Less Debt)
Revenue Growth
-1.8%
This Stock
vs
124.04%
Sector Avg
-101.5% (Slower)
Current Ratio
4.02
This Stock
vs
4.47
Sector Avg
-10.1% (Weaker)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

PETERS WILLIAM J
Chief Financial Officer
Stock Award
2026-03-09
58,693 shares
ZHANG JACK YONGFENG
Chief Executive Officer
Stock Award
2026-03-09
252,966 shares
ZHOU RONG
Officer
Stock Award
2026-03-09
39,432 shares
LIAWATIDEWI YAKOB
Officer and Director
Stock Award
2026-03-09
35,450 shares
ZHOU RONG
Officer
Option Exercise
2025-12-17
9,787 shares · $110,887
ZHOU RONG
Officer
Sell
2025-12-17
9,787 shares · $256,379
PETERSEN FLOYD F
Director
Sell
2025-12-12
4,163 shares · $107,508
PRINS RICHARD K
Director
Option Exercise
2025-11-25
4,179 shares · $69,748
PRINS RICHARD K
Director
Sell
2025-11-25
4,179 shares · $113,253
PETERSEN FLOYD F
Director
Option Exercise
2025-11-13
16,679 shares · $278,373
PETERSEN FLOYD F
Director
Sell
2025-11-13
16,679 shares · $441,837
PETERSEN FLOYD F
Director
Sell
2025-11-03
500 shares · $12,633
PETERSEN FLOYD F
Director
Sell
2025-10-01
500 shares · $13,602
Insider transactions can signal confidence or concerns about company prospects

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
7 analysts
Wells Fargo
2026-02-27
Maintains
Overweight Overweight
Needham
2026-02-27
Maintains
Buy Buy
Barclays
2025-12-09
init
Equal-Weight
Needham
2025-11-07
Maintains
Buy Buy
Needham
2025-10-22
reit
Buy Buy

Past News Coverage

Recent headlines mentioning AMPH from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI Chat
Markets
Profile